ACE2 and COVID-19: The specificity of the assay was also high, with RBD-ACE2 binding specifically blocked by sera from the COVID-19 convalescent panel (mean inhibitory IgG titer 1 : 109; 95% CI, 1 : 86 to 1 : 131; Figure 3(b)).